Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study
This study is for long term follow up of efficacy and safety for any patient treated with MB-105 who has consented to joining the LTFU study. There are no exclusion criteria.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Open Observation | All patients who previously received MB-105 on another study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MB-105 | Biological | This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Assess long term safety of MB-105 in patients who received MB-105 | SAEs | 15 Years |
| Measure | Description | Time Frame |
|---|---|---|
| Assess long term efficacy of MB-105 in patients who received MB-105 | Time to progression/relapse in those who have not yet relapsed and overall survival | 15 Years |
Not provided
Inclusion Criteria:
Received MB-105 Signed informed consent Agree to transfer of samples from previous study Able to comply with study requirements
Exclusion Criteria:
N/A
Not provided
Not provided
Not provided
Not provided
Patients who previously received MB-105 and consent to participate
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided